Icotrokinra: Side Effects

Safety Overview#

Icotrokinra has demonstrated a favorable safety profile across the ICONIC Phase 3 clinical program, with adverse event rates comparable to placebo. Pooled safety data from over 3,000 patients across four Phase 3 trials showed adverse events in 49.1% of icotrokinra-treated patients vs 51.9% in placebo groups, with no new safety signals identified.

A distinguishing feature of icotrokinra's safety profile is the absence of injection site reactions, which are common with injectable biologics. As an oral tablet, icotrokinra eliminates this class of adverse events entirely.

Common Adverse Events#

The most commonly reported adverse events in the ICONIC trials occurred at balanced rates between icotrokinra and placebo:

Nasopharyngitis#

• Most common adverse event in both icotrokinra and placebo groups
• Not considered treatment-related based on similar incidence in both arms
• Mild severity in the majority of cases

Upper Respiratory Tract Infection#

• Second most common adverse event
• Rates comparable between icotrokinra and placebo
• No indication of increased susceptibility to respiratory infections

Headache#

• Reported at similar rates in treatment and placebo groups
• Generally mild and self-limiting

Adverse Event Summary#

Safety in High-Impact Site Psoriasis#

In the ICONIC-TOTAL trial evaluating icotrokinra for scalp and genital psoriasis, adverse events were reported in 50% of the treatment group vs 42% in placebo. The slightly higher rate in the treatment group was not driven by any specific serious adverse event category.

Comparison with Other Oral Therapies#

vs Deucravacitinib (TYK2 Inhibitor)#

Deucravacitinib has a generally favorable safety profile for an oral therapy, though it affects multiple cytokine pathways (IL-23, IL-12, type I interferons). Icotrokinra's selective IL-23R blockade may offer a more targeted safety profile, though head-to-head safety comparisons from the ICONIC-ADVANCE trials did not reveal significant differences.

vs JAK Inhibitors#

JAK inhibitors carry FDA boxed warnings for serious infections, cardiovascular events, malignancy, and thrombosis. Icotrokinra's selective mechanism is expected to avoid these class-wide safety concerns, consistent with the favorable safety profile of injectable IL-23 antibodies.

Theoretical Safety Considerations#

Immunosuppression#

IL-23 drives Th17 immunity, which is important for defense against extracellular bacteria and fungi (particularly mucocutaneous candidiasis). While injectable IL-23 inhibitors have shown minimal infectious risk, the oral route and daily dosing of icotrokinra represent a different pharmacokinetic profile that warrants continued surveillance.

Long-term Outcomes#

Clinical trial data currently extend to approximately 52 weeks. Longer-term safety data from extension studies are needed to fully characterize risks of sustained IL-23R blockade, particularly regarding:

• Malignancy rates
• Cardiovascular events
• Opportunistic infections
• Immunogenicity

Contraindications#

• Active serious infections: Treatment should not be initiated in patients with active infections, consistent with guidelines for all IL-23 pathway therapies
• Hypersensitivity: Known allergy to icotrokinra or excipients

Drug Interactions#

No clinically significant drug interactions have been identified. As a macrocyclic peptide that does not undergo hepatic metabolism via cytochrome P450 enzymes, icotrokinra is not expected to interact with CYP-metabolized drugs. Live vaccines should be avoided during treatment, consistent with recommendations for other immunomodulatory therapies.

Related Reading#

• Icotrokinra overview and research guide
• Icotrokinra risks and regulatory status
• Icotrokinra dosing protocols